Metabolomics Market Worth $2.38 billion | Growing Demand for Personalized Medicine

metabolomics market

PUNE, India, 2020-May-26 — /EPR Network/ —

MarketsandMarkets forecasts the Metabolomics Market to grow USD 2.38 billion, at a Compound Annual Growth Rate (CAGR) of 14.6% during the forecast period.

Growing Demand for Personalized Medicine Drive the Metabolomics Market

The growing focus on personalized medicine has driven the use of metabolomics tools by manufacturers engaged in developing rigorous strategies for understanding the root of a disease rather than simply treating a patient’s symptoms. Recent developments in analytical technologies, such as the emergence of high-resolution mass spectrometry, have provided revolutionary analytical capabilities in metabolomics, offering the detection of more than 10,000 metabolites at a given point of time. Such developments are opening new opportunities for the utilization of metabolomics in the development of personalized and precision medicine.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=900

By application, the lung diffusion mixtures segment to accounted for the largest share of the market

Based on applications, the biomarker discovery segment accounted for the largest share of the global metabolomics market. The rising prevalence and incidence of chronic diseases such as cardiac diseases, cancer, and diabetes; growing acceptance of cancer diagnostic tests; and scientific progression in discovery technologies are major factors driving market growth in this segment.

By indication, the hospitals segment accounted for the largest share of the market

Based on indication, the cancer segment accounted for the largest share of the global metabolomics market, in 2015. The large share of this segment can be attributed to the increasing utility of biomarkers in patient stratification and the drug development process and increasing scientific progression in discovery technologies.

Opportunity: Biomarker development

Metabolomics is used for the identification of new biomarkers through the use of bioinformatics tools, which indicate the changes in the physiological state of a cell or tissue. Biomarkers are important for the development of in vitro diagnostic tools, environmental toxicology screening methods, and drug discovery and development techniques. The omics revolution of the last decade has increased the application of metabolomics in biomedical research. As a result of these technological developments, new biomarkers are being regularly discovered.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=900

APAC to grow at the highest CAGR during the forecast period.

North America is expected to hold the largest market size in the metabolomics market during the forecast period, followed by the European region. On the other hand, the Asia Pacific market is expected to witness the highest growth during the forecast period. Growth in this region can be attributed to the huge demand for metabolomics in drug discovery and biomarker development experiments.

The global metabolomics market is highly competitive and fragmented in nature. Prominent players in the global metabolomics market are Thermo Fisher Scientific (U.S.), Agilent Technologies (U.S.), Danaher Corporation (U.S.), Waters Corporation (U.S.), and Shimadzu Corporation (Japan). Other leading players in this market include Bio-Rad Laboratories (U.S.), Bruker Corporation (U.S.), Biocrates Life Sciences AG (Austria), Human Metabolome Technologies Inc. (Japan)